Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in...
Kapitonova M. Y., Alyautdin R. N., Wan-Syazli R. W. A. L., Nor-Ashikin M. N. K., Ahmad A., Norita S., Dy'dy'kin S. S.
Bulletin of Russian State Medical University
Vol.7, Issue6, P. 107-112
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.24075/brsmu.2018.072
Аннотация:
Parkinson disease is one of the common age-related motor neurodegenerative diseases, in which dopamine neurons degeneration is considered to be pathognomic for the development of motor disfunction. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, which is considered to be a key regulator of neuronal plasticity. BDNF, being a large molecule, does not pass through the blood-brain barrier (BBB). Synthetic polymer nanoparticles (NP), covered by surfactant, provide the phenomenon of “Trojan hoarse” and enable BDNF to penetrate into the brain tissue. For modelling of parkinsonism we used an intraperitoneal (i.p.) injection of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) which was injected to the C57BL/6 mice with subsequest treatment with normal saline (group 1), BDNF (group 2), nanoparticulate BDNF (group 3) and surfactant-coated nanoparticulate BDNF (group 4). After 90 min, 24 hours, 72 hours and 7 days manifestations of parkinsonism were e
Ключевые слова:
Blood-brain barrier; Brain-derived neurotrophic factor; ELISA; Nanoparticles; Parkinsonism
Язык текста: Английский
ISSN: 2542-1204
Kapitonova M. Y. M.Yu.
Alyautdin R. N.
Wan-Syazli R. W. A. L.
Nor-Ashikin M. N. K.
Ahmad A.
Norita S.
Dy'dy'kin S. S. Sergej Sergeevich 1960-
Капитонова М. Y. М.Ю.
Аляутдин Р. Н.
Wан-Сязли Р. W. А. Л.
Нор-Ашикин М. Н. К.
Ахмад А.
Норита С.
Дыдыкин С. С. Сергей Сергеевич 1960-
Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism
Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in...
Текст визуальный непосредственный
Bulletin of Russian State Medical University
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
Vol.7, Issue6 P. 107-112
2018
Статья
Blood-brain barrier Brain-derived neurotrophic factor ELISA Nanoparticles Parkinsonism
Parkinson disease is one of the common age-related motor neurodegenerative diseases, in which dopamine neurons degeneration is considered to be pathognomic for the development of motor disfunction. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, which is considered to be a key regulator of neuronal plasticity. BDNF, being a large molecule, does not pass through the blood-brain barrier (BBB). Synthetic polymer nanoparticles (NP), covered by surfactant, provide the phenomenon of “Trojan hoarse” and enable BDNF to penetrate into the brain tissue. For modelling of parkinsonism we used an intraperitoneal (i.p.) injection of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) which was injected to the C57BL/6 mice with subsequest treatment with normal saline (group 1), BDNF (group 2), nanoparticulate BDNF (group 3) and surfactant-coated nanoparticulate BDNF (group 4). After 90 min, 24 hours, 72 hours and 7 days manifestations of parkinsonism were e